!!
Identification of a Novel Hepatitis #C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 #Genotypes
https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy401/5047409?redirectedFrom=fulltext
Four patients, previously classified as GT5 by LiPA or Abbott RealTime polymerase chain reaction assays, were identified as infected with a novel HCV GT. This novel HCV GT, GT8, is genetically distinct from previously identified HCV GT1–7 with >30% nucleotide sequence divergence to the established HCV subtypes. All 4 patients were originally from Punjab, India, but now reside in Canada and are epidemiologically unlinked. Despite presence of baseline resistance-associated substitutions within the GT8 virus of all 4 patients (NS3: V36L, Q80K/R; NS5A: Q30S, Y93S), all patients achieved a sustained virologic response; 2 treated with sofosbuvir/velpatasvir/voxilaprevir for 8 weeks, 1 with sofosbuvir/ledipasvir plus ribavirin for 24 weeks and 1 with sofosbuvir plus daclatasvir for 12 weeks.
Conclusions
The discovery of a novel HCV GT8 confirms the circulation of this newly identified lineage in the human population.
Identification of a Novel Hepatitis #C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 #Genotypes
https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy401/5047409?redirectedFrom=fulltext
Four patients, previously classified as GT5 by LiPA or Abbott RealTime polymerase chain reaction assays, were identified as infected with a novel HCV GT. This novel HCV GT, GT8, is genetically distinct from previously identified HCV GT1–7 with >30% nucleotide sequence divergence to the established HCV subtypes. All 4 patients were originally from Punjab, India, but now reside in Canada and are epidemiologically unlinked. Despite presence of baseline resistance-associated substitutions within the GT8 virus of all 4 patients (NS3: V36L, Q80K/R; NS5A: Q30S, Y93S), all patients achieved a sustained virologic response; 2 treated with sofosbuvir/velpatasvir/voxilaprevir for 8 weeks, 1 with sofosbuvir/ledipasvir plus ribavirin for 24 weeks and 1 with sofosbuvir plus daclatasvir for 12 weeks.
Conclusions
The discovery of a novel HCV GT8 confirms the circulation of this newly identified lineage in the human population.